GSK Trizivir

Direct-to-consumer campaign for HIV therapy Trizivir will begin shortly, company says. Trizivir - a triple combination of abacavir, lamivudine and zidovudine - is cited as a "possible exception" in an FDA advisory that DTC ads should emphasize that HIV therapies "should be taken only in combination with other drugs for HIV infection." Some DTC campaigns display images "not representative of HIV infection," and fail to show limitations of HIV therapies prominently, FDA advisory letter states. The letter, signed by FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams, was sent April 27 to eight HIV drug makers, who have 90 days to revise materials